Last10K.com

Arch Therapeutics, Inc. (ARTH) SEC Filing 10-Q Quarterly Report for the period ending Wednesday, June 30, 2021

SEC Filings

ARTH Registration of Securities

Arch Therapeutics, Inc.

CIK: 1537561 Ticker: ARTH
Document And Entity Information - shares
9 Months Ended
Jun. 30, 2021
Aug. 12, 2021
Document And Entity Information  
Document Type10-Q 
Amendment Flagfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Document Period End DateJun. 30, 2021 
Document Fiscal Year Focus2021 
Document Fiscal Period FocusQ3 
Entity File Number000-54986 
Entity Incorporation, State or Country CodeNV 
Entity Registrant NameArch Therapeutics, Inc. 
Entity Tax Identification Number46-0524102 
Entity Address, Address Line One235 Walnut Street 
Entity Address, Address Line TwoSuite 6 
Entity Address, City or TownFramingham 
Entity Address, CountryMA 
Entity Address, Postal Zip Code01702 
City Area Code617 
Local Phone Number431-2313 
Entity Central Index Key0001537561 
Current Fiscal Year End Date--09-30 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Shell Companyfalse 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Common Stock, Shares Outstanding 236,719,770

View differences made from one quarter to another to evaluate Arch Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Arch Therapeutics, Inc..

Continue

Assess how Arch Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Arch Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' Equity (Deficit)
Consolidated Statements Of Operations
2021 Registered Direct Offering
2021 Registered Direct Offering (Details)
2021 Registered Direct Offering - Additional Information (Details)
Basis Of Presentation And Description Of Business
Convertible Notes
Convertible Notes (Details)
Derivative Liabilities
Derivative Liabilities (Tables)
Derivative Liabilities - Additional Information (Details)
Derivative Liabilities - Derivative Liabilities Using Black Scholes Model (Details)
Derivative Liabilities - Fair Value Of Derivative (Details)
Inventories
Inventories (Details)
Inventories (Tables)
Issuance And Treatment Of The Series D, Series And Series J Warrants
Issuance And Treatment Of The Series D, Series And Series J Warrants - Additional Information (Details)
October 2019 Registered Direct Offering
October 2019 Registered Direct Offering (Details)
Payroll Protection Program Loan
Payroll Protection Program Loan (Details)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Property And Equipment - Additional Information (Details)
Registered Direct Offerings
Registered Direct Offerings - Additional Information (Details)
Risks And Uncertainties - Covid-19
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Restricted Stock Activity (Details)
Stock-Based Compensation - Stock Compensation Activity (Details)
Stock-Based Compensation - Weighted Average Restricted Stock (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Arch Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ARTH
CIK: 1537561
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-21-104937
Submitted to the SEC: Fri Aug 13 2021 1:40:33 PM EST
Accepted by the SEC: Fri Aug 13 2021
Period: Wednesday, June 30, 2021
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/arth/0001104659-21-104937.htm